Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anaïs Glatard

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
European Journal of Clinical Pharmacology|March 15, 2019
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general populationAnaïs Glatard, Monia Guidi, Maria Dobrinas, et al.
Clinical Pharmacokinetics|May 26, 2025
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of AcromegalyAnaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, et al.
Antimicrobial Agents and Chemotherapy|March 11, 2015
Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patientsAnaïs Glatard, Laurent Bourguignon, Roger W Jelliffe, et al.
Experimental and Clinical Psychopharmacology|October 20, 2017
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapyAnaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, et al.
Toxicology and Applied Pharmacology|August 2, 2015
Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug developmentAnaïs Glatard, Aliénor Berges, Tarjinder Sahota, et al.
Clinical and Translational Science|November 27, 2024
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemiaPavan Vaddady, Anaïs Glatard, Giovanni Smania, et al.
Basic & Clinical Pharmacology & Toxicology|March 18, 2021
Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric populationAurélie Delacrétaz, Anaïs Glatard, Céline Dubath, et al.
Clinical Pharmacokinetics|September 26, 2019
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic AnalysesAnaïs Glatard, Monia Guidi, Aurélie Delacrétaz, et al.
British Journal of Clinical Pharmacology|May 31, 2019
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainmentPerrine Courlet, Monia Guidi, Anaïs Glatard, et al.
Pharmacogenetics and Genomics|September 26, 2017
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugsAurélie Delacrétaz, Patricia Lagares Santos, Nuria Saigi Morgui, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
European Journal of Clinical Pharmacology|March 15, 2019
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general populationAnaïs Glatard, Monia Guidi, Maria Dobrinas, et al.
Clinical Pharmacokinetics|May 26, 2025
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of AcromegalyAnaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, et al.
Antimicrobial Agents and Chemotherapy|March 11, 2015
Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patientsAnaïs Glatard, Laurent Bourguignon, Roger W Jelliffe, et al.
Experimental and Clinical Psychopharmacology|October 20, 2017
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapyAnaïs Glatard, Maria Dobrinas, Mehdi Gholamrezaee, et al.
Toxicology and Applied Pharmacology|August 2, 2015
Comparing probabilistic and descriptive analyses of time-dose-toxicity relationship for determining no-observed-adverse-effect level in drug developmentAnaïs Glatard, Aliénor Berges, Tarjinder Sahota, et al.
Clinical and Translational Science|November 27, 2024
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemiaPavan Vaddady, Anaïs Glatard, Giovanni Smania, et al.
Basic & Clinical Pharmacology & Toxicology|March 18, 2021
Valproate is associated with early decrease of high-density lipoprotein cholesterol levels in the psychiatric populationAurélie Delacrétaz, Anaïs Glatard, Céline Dubath, et al.
Clinical Pharmacokinetics|September 26, 2019
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic AnalysesAnaïs Glatard, Monia Guidi, Aurélie Delacrétaz, et al.
British Journal of Clinical Pharmacology|May 31, 2019
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainmentPerrine Courlet, Monia Guidi, Anaïs Glatard, et al.
Pharmacogenetics and Genomics|September 26, 2017
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugsAurélie Delacrétaz, Patricia Lagares Santos, Nuria Saigi Morgui, et al.
Pageof 2